| [1] |
XU XH, ZENG XY, WANG LJ, et al. The disease burden of pancreatic cancer in China in 1990 and 2017[J]. Chin J Epidemiol, 2019, 40(9): 1084-1088.
徐晓慧, 曾新颖, 王黎君, 等. 1990年与2017年中国胰腺癌疾病负担分析[J]. 中华流行病学杂志, 2019, 40(9): 1084-1088.
|
| [2] |
PILGRIM C, TE MARVELDE L, STUART E, et al. Population-based analysis of treatment patterns and outcomes for pancreas cancer in Victoria[J]. ANZ J Surg, 2020, 90(9): 1677-1682. DOI: 10.1111/ans.15721 |
| [3] |
CARAVATTA L, CELLINI F, SIMONI N, et al. Magnetic resonance imaging (MRI) compared with computed tomography (CT) for interobserver agreement of gross tumor volume delineation in pancreatic cancer: A multi-institutional contouring study on behalf of the AIRO group for gastrointestinal cancers[J]. Acta Oncol, 2019, 58(4): 439-447. DOI: 10.1080/0284186X.2018.1546899 |
| [4] |
DIFFENDERFER ES, VERGINADIS Ⅱ, KIM MM, et al. Design, implementation, and in vivo validation of a novel proton FLASH radiation therapy system[J]. Int J Radiat Oncol Biol Phys, 2020, 106(2): 440-448. DOI: 10.1016/j.ijrobp.2019.10.049 |
| [5] |
BOURHIS J, SOZZI WJ, JORGE PG, et al. Treatment of a first patient with FLASH-radiotherapy[J]. Radiother Oncol, 2019, 139: 18-22. DOI: 10.1016/j.radonc.2019.06.019 |
| [6] |
XIANG M, HEESTAND GM, CHANG DT, et al. Neoadjuvant treatment strategies for resectable pancreas cancer: A propensity-matched analysis of the National Cancer Database[J]. Radiother Oncol, 2020, 143: 101-107. DOI: 10.1016/j.radonc.2020.01.007 |
| [7] |
TCHELEBI LT, LEHRER EJ, TRIFILETTI DM, et al. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer(CRiSP): An international systematic review and meta-analysis[J]. Cancer, 2020, 126(10): 2120-2131. DOI: 10.1002/cncr.32756 |
| [8] |
BERTHOLET J, HUNT A, DUNLOP A, et al. Comparison of the dose escalation potential for two hypofractionated radiotherapy regimens for locally advanced pancreatic cancer[J]. Clin Transl Radiat Oncol, 2019, 16: 21-27. DOI: 10.1016/j.ctro.2019.03.001 |
| [9] |
AZIZ H, ZEESHAN M, JIE T, et al. Neoadjuvant chemoradiation therapy is associated with adverse outcomes in patients undergoing pancreaticoduodenectomy for pancreatic cancer[J]. Am Surg, 2019, 85(11): 1276-1280. DOI: 10.1177/000313481908501136 |
| [10] |
KAMARAJAH SK, BUNDRED JR, BOYLE C, et al. Impact of neoadjuvant therapy on post-operative pancreatic fistula: A systematic review and meta-analysis[J]. ANZ J Surg, 2020, 90(11): 2201-2210. DOI: 10.1111/ans.15885 |
| [11] |
THANIKACHALAM K, DAMARLA V, SEIXAS T, et al. Neoadjuvant Phase Ⅱ trial of chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer[J]. Am J Clin Oncol, 2020, 43(6): 435-441. DOI: 10.1097/COC.0000000000000688 |
| [12] |
TRAN NH, SAHAI V, GRIFFITH KA, et al. Phase 2 trial of neoadjuvant FOLFIRINOX and intensity modulated radiation therapy concurrent with fixed-dose rate-gemcitabine in patients with borderline resectable pancreatic cancer[J]. Int J Radiat Oncol Biol Phys, 2020, 106(1): 124-133. DOI: 10.1016/j.ijrobp.2019.08.057 |
| [13] |
EGUCHI H, TAKEDA Y, TAKAHASHI H, et al. A prospective, open-label, multicenter phase 2 trial of neoadjuvant therapy using full-dose gemcitabine and S-1 concurrent with radiation for resectable pancreatic ductal adenocarcinoma[J]. Ann Surg Oncol, 2019, 26(13): 4498-4505. DOI: 10.1245/s10434-019-07735-8 |
| [14] |
VERSTEIJNE E, SUKER M, GROOTHUIS K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Results of the dutch randomized phase Ⅲ PREOPANC trial[J]. J Clin Oncol, 2020, 38(16): 1763-1773. DOI: 10.1200/JCO.19.02274 |
| [15] |
LUTSYK M, BEN-YOSEF R. The role of radiotherapy in resected r0/r+ pancreatic cancer: A real-life single-institution experience[J]. Am J Clin Oncol, 2020, 43(3): 187-192. DOI: 10.1097/COC.0000000000000653 |
| [16] |
KAMARAJAH SK, SONNENDAY CJ, CHO CS, et al. Association of adjuvant radiotherapy with survival after margin-negative resection of pancreatic ductal adenocarcinoma: A propensity-matched National Cancer Database (NCDB) Analysis[J]. Ann Surg, 2021, 273(3): 587-594. DOI: 10.1097/SLA.0000000000003242 |
| [17] |
SHEN ZT, ZHOU H, LI AM, et al. Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer[J]. J Cancer Res Clin Oncol, 2020, 146(2): 417-428. DOI: 10.1007/s00432-019-03066-z |
| [18] |
ARCELLI A, GUIDO A, BUWENGE M, et al. Higher biologically effective dose predicts survival in sbrt of pancreatic cancer: A multicentric analysis (PAULA-1)[J]. Anticancer Res, 2020, 40(1): 465-472. DOI: 10.21873/anticanres.13975 |
| [19] |
ZHANG AM, CHANG XY, LI WG, et al. Clinical effect of CyberKnife radiosurgery in locally advanced pancreatic cancer or pancreatic cancer with distant metastasis[J]. J Clin Hepatol, 2019, 35(1): 143-146. DOI: 10.3969/j.issn.1001-5256.2019.01.027 |
| [20] |
SCORSETTI M, COMITO T, FRANCESCHINI D, et al. Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question[J]. Br J Radiol, 2020, 93(1106): 20190627. DOI: 10.1259/bjr.20190627 |
| [21] |
SHI W, JIANG R, LIANG F, et al. Definitive chemoradiotherapy and salvage chemotherapy for patients with isolated locoregional recurrence after radical resection of primary pancreatic cancer[J]. Cancer Manag Res, 2019, 11: 5065-5073. DOI: 10.2147/CMAR.S202543 |
| [22] |
LI Y, LIU W, ZHAO L, et al. The main bottleneck for non-metastatic pancreatic adenocarcinoma in past decades: A population-based analysis[J]. Med Sci Monit, 2020, 26: e921515.
|
| [23] |
KHATTAB A, PATRUNI S, ABEL S, et al. Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma[J]. J Gastrointest Oncol, 2019, 10(5): 918-927. DOI: 10.21037/jgo.2019.07.02 |
| [24] |
GARNIER J, EWALD J, MARCHESE U, et al. Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: A prospective cohort study[J]. BMC Cancer, 2020, 20(1): 203. DOI: 10.1186/s12885-020-6690-1 |
| [25] |
PARR E, DU Q, ZHANG C, et al. Radiomics-based outcome prediction for pancreatic cancer following stereotactic body radiotherapy[J]. Cancers (Basel), 2020, 12(4)L 1051. DOI: 10.3390/cancers12041051 |
| [26] |
SIMPSON G, SPIELER B, DOGAN N, et al. Predictive value of 0.35 T magnetic resonance imaging radiomic features in stereotactic ablative body radiotherapy of pancreatic cancer: A pilot study[J]. Med Phys, 2020, 47(8): 3682-3690. DOI: 10.1002/mp.14200 |
| [27] |
SU W, REN S, ZHU X, et al. Standardized thresholds of volume-based PET/CT parameters predicting survival of patients with pancreatic head cancer treated with stereotactic body radiation therapy[J]. Ann Nucl Med, 2020, 34(6): 379-387. DOI: 10.1007/s12149-020-01454-x |
| [28] |
INCERTI E, VANOLI EG, BROGGI S, et al. Early variation of 18-fluorine-labelled fluorodeoxyglucose PET-derived parameters after chemoradiotherapy as predictors of survival in locally advanced pancreatic carcinoma patients[J]. Nucl Med Commun, 2019, 40(10): 1072-1080. DOI: 10.1097/MNM.0000000000001065 |
DownLoad: